The Current Ratio as of November 2024 (TTM) for Arcus Biosciences, Inc. (RCUS) is 5.14

According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.14. This represents a change of 6.56% compared to the average of 4.82 of the last 4 quarters.

Arcus Biosciences, Inc. (RCUS) Historical Current Ratio (quarterly & annually)

How has RCUS Current Ratio performed in the past?

The mean historical Current Ratio of Arcus Biosciences, Inc. over the last ten years is 9.48. The current 5.14 Current Ratio has changed 5.32% with respect to the historical average. Over the past ten years (40 quarters), RCUS's Current Ratio was at its highest in in the March 2018 quarter at 19.78. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Arcus Biosciences, Inc. (RCUS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Arcus Biosciences, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arcus Biosciences, Inc. (RCUS) Average Current Ratio

How has RCUS Current Ratio performed in the past?

The current Current Ratio of Arcus Biosciences, Inc. (RCUS) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Arcus Biosciences, Inc. (RCUS) Current Ratio vs. Peers

How is RCUS’s Current Ratio compared to its peers?

Arcus Biosciences, Inc.’s Current Ratio is less than Cullinan Oncology, Inc. (28.87), less than Annexon, Inc. (21.81), less than Structure Therapeutics Inc. (41.38), less than Relay Therapeutics, Inc. (15.64), less than Day One Biopharmaceuticals, Inc. (14.62), less than Acumen Pharmaceuticals, Inc. (17.37), less than X4 Pharmaceuticals, Inc. (6.07), less than Inozyme Pharma, Inc. (9.84), less than VectivBio Holding AG (9.14), greater than PTC Therapeutics, Inc. (2.23), greater than Blueprint Medicines Corporation (3.32), less than Krystal Biotech, Inc. (7.97), greater than Intercept Pharmaceuticals, Inc. (4.22), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Immix Biopharma, Inc. (7.00), greater than CNS Pharmaceuticals, Inc. (0.31), less than Hepion Pharmaceuticals, Inc. (5.62), greater than Freeline Therapeutics Holdings plc (1.95), less than AVROBIO, Inc. (26.17), less than Icosavax, Inc. (18.06), greater than Apellis Pharmaceuticals, Inc. (5.08), less than iTeos Therapeutics, Inc. (18.08), less than TScan Therapeutics, Inc. (7.77),

Build a custom stock screener for Arcus Biosciences, Inc. (RCUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arcus Biosciences, Inc. (RCUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.